Important pharmacogenomic aspects in the management of HIV/AIDS

A. Marais*, E. Osuch, V. Steenkamp, L. Ledwaba

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


In managing HIV/AIDS with highly active antiretroviral agents, the historical therapeutic aim remains to maintain the plasma concentrations at a level above the half maximal inhibitory concentration (IC50) required for 50% inhibition in viral replication. Concentration dependent toxicity is often observed in patients with elevated drug exposure and high peak plasma levels in lieu of accurately calculated drug dosages. Similarly low plasma concentrations are frequently witnessed in individuals receiving adequate dosage regimens. Pharmacogenetic variations in drug metabolizing enzymes may contribute to this phenomenon. Over the last decade, knowledge about the role of pharmacogenetics in the treatment and prediction of ARV plasma levels have increased significantly. However, the extent of these genetic variations remain largely unknown in the South African population, which has sparked a renewed enthusiasm for local pharmacogenetic studies.

Original languageEnglish
Article numbera5047
Pages (from-to)17-20
Number of pages4
JournalSouth African Family Practice
Issue number1
Publication statusPublished - 1 Jan 2019
Externally publishedYes


  • CYP450
  • Genetic polymorphisms
  • Non-nucleoside reverse transcriptase inhibitors
  • Nucleoside reverse transcriptase inhibitors
  • Protease inhibitors


Dive into the research topics of 'Important pharmacogenomic aspects in the management of HIV/AIDS'. Together they form a unique fingerprint.

Cite this